Key Report Stats

Release Date: September 2024
Number of Pages: 327
Tables and Figures: 50
Companies Profiles: 82
Pipeline Candidates: 236
The “Dermatological Drugs Market: 2024 – 2034 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the dermatological drugs ecosystem including dermatological disorders, application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for dermatological drugs from 2024 through to 2034. The forecasts are segmented for over 7 therapeutic categories, 5 regions and 26 leading countries. 

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and 2024 clinical pipeline dataset.

For Enquiries, Press, Sample Pages and Table of Contents Please Contact: [email protected]

The Dermatological Drugs Market: 2024 – 2034 - Opportunities, Challenges, Strategies & Forecasts​

Synopsis: The global dermatological drugs market is experiencing rapid growth, driven by an increasing prevalence of skin disorders and a rising demand for innovative therapies. Companies are actively expanding their portfolios to address diverse dermatological conditions, capitalizing on unmet medical needs and the push for more targeted, high-efficacy treatments. This strategic shift is reshaping the industry landscape, with breakthroughs in biologics, biosimilars, and novel therapies for conditions like psoriasis, atopic dermatitis, and skin cancer, positioning the sector for explosive growth in 2024 and beyond.

Although surgery and other therapies are widely used for the treatment of certain skin conditions, dermatological drugs continue to account for the highest percentage of spending within the wider market for dermatology products. Expected to reach nearly $45 Billion in global spending by the end of 2024, dermatological drugs remain the preferred approach to treat common skin disorders, ranging from acne to more complicated conditions such as psoriasis. Despite the loss of patent protection for several blockbuster drugs which has attracted generic competition, the market is ripe for future growth with several novel drugs in late-stage development.

Within this evolving landscape, biologics have emerged as a game-changer, particularly for chronic skin conditions like psoriasis, atopic dermatitis, and alopecia areata. These therapies, derived from living cells, offer targeted treatment options with improved efficacy, providing new hope for patients who have not responded well to traditional treatments. 

Simultaneously, advancements in drug delivery systems, especially in topical formulations, are playing a crucial role in market growth. Innovative delivery platforms such as microneedle technology, are enhancing the penetration of active ingredients into the skin while minimizing side effects and improving tolerability, even on compromised skin. 
Pricing: Single User to Global Access

​Single User License: USD 3,000
Company Wide License (Single Site): USD 4,500
Company Wide License (Global Site): USD 7,500

For a Sample and Table of Contents please contact: [email protected]
Topics Covered:
The report covers the following topics:
  • Dermatological drugs ecosystem
  • Market drivers and barriers
  • Dermatological disorders, application areas and key trends
  • Analysis of key drug classes and leading dermatological drugs
  • Future drug development pipeline
  • Dermatological drug delivery technologies
  • Industry roadmap and value chain
  • Profiles and strategies of 82 leading ecosystem players, including dermatological drug developers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2024 till 2034
Sample Figure: Distribution of Dermatological Pipeline Candidates by Phase (%)
The “Dermatological Drugs Market: 2024 – 2034 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the dermatological drugs ecosystem including dermatological disorders, application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for dermatological drugs from 2024 through to 2034. The forecasts are segmented for over 7 therapeutic categories, 5 regions and 26 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and 2024 clinical pipeline dataset.
Key Findings:
The report has the following key findings
  • Expected to reach nearly $45 Billion in global spending by the end of 2024, dermatological drugs remain the preferred approach to treat common skin disorders, ranging from acne to more complicated conditions such as akronpsoriasis.
  • Biologics continue to dominate the dermatological drugs market, with recent major approvals driving growth. Notable approvals include Adbry (tralokinumab) for atopic dermatitis, Dupixent (dupilumab) expanded indications for chronic spontaneous urticaria and prurigo nodularis, and Bimzelx (bimekizumab) for plaque psoriasis in Europe.
  • Novel biologics such as Dupilumab (targeting IL-4 and IL-13) continue to dominate the market for atopic dermatitis, while newer therapies like Bimekizumab, which targets both IL-17A and IL-17F, are emerging as key treatments for psoriasis.
  • New drug development programs for psoriasis and atopic dermatitis in 2024 are focused on targeting selective interleukins, including IL-4, IL-13, IL-17, IL-23, and IL-31, with several recent advancements.
  • IL-23 inhibitors like Risankizumab and Guselkumab are gaining traction as they offer improved safety profiles and durable efficacy compared to earlier therapies. These interleukin inhibitors represent a growing trend toward more targeted and effective therapies, addressing both moderate to severe cases and offering long-term control.
  • Other programs include but are not limited to PD-L1 (Programmed Death Ligand-1) antibodies; topical treatments such as JAK (Janus Kinase) inhibitors, TYIs (Tyrosine Kinase Inhibitors) and PDE-4 (Phosphodiesterase-4) inhibitors; MEK and BRAF inhibitors; and new classes of antibiotics.
  • The market is continuing to consolidate with several prominent acquisitions and partnerships such as the recent acquisition of U.S. based Proteologix by J&J. This acquisition is crucial for dermatology, as it includes two pre-clinical bispecific antibodies, PX-128 and PX-130, targeting pathways in atopic dermatitis.
Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the dermatological drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2024 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • What are the prospects of biosimilar drugs in dermatology?
  • What are the key drug delivery technologies being used in dermatological treatments?
  • How big is the market for Psoriasis drugs?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should dermatological drug manufacturers adopt to remain competitive? ​
Sample Figure:
Figure: Distribution of Dermatological Pipeline Candidates by Indication (%)
Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Therapeutic Category
    • Acne & Rosacea
    • Alopecia & Hair Disorders
    • Dermatitis
    • Psoriasis
    • Skin Infections
    • Skin Cancer
    • Other Conditions​​
  • Regional Markets
    • Latin & Central America
    • North America
    • Middle East & Africa
    • Europe
    • ​Asia Pacific​​
  • Country Markets
    • Australia 
    • ​Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico​
​
  • Netherlands
  • Poland
  • Portugal
  • Russia
  • Saudi Arabia
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Turkey
  • UK
  • USA
List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report
3M
Abbott Laboratories
AbbVie
Abeona Therapeutics
AboundBio
Absci Corporation 
Aclaris Therapeutics
Actavis Generics 
Actelion Pharmaceuticals
Adaptimmune
AiCuris
Akros Pharma
Alchemee
Alfasigma
Allergan
Almirall 
AltruBio 
Amgen
Amplyx Pharmaceuticals
Amryt Pharma (Chiesi Farmaceutici)
Anacor Pharmaceuticals 
AnaptysBio
AndroScience Corporation
AnnJi Pharmaceutical
AOBiome
ApoPharma
Apotex 
Aqua Pharmaceuticals
Arcutis Biotherapeutics
Arena Pharmaceuticals
arGentis Pharmaceuticals
Array BioPharma 
Asana BioSciences
ASLAN Pharmaceuticals
Assertio Therapeutics
Astellas Pharma 
AstraZeneca
Autotelic
Basilea Pharmaceutica
Bausch & Lomb
Bausch Health Company
Bayer
Bayer Pharmaceuticals
Bill and Melinda Gates Foundation
Biocon
Biofrontera
Biogen
BioMimetix
BioNTech
Biosintez
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
Botanix Pharma
BPGbio
Bristol Myers Squibb 
Cadila Healthcare (Now Zydus)
Candesant Biomedical
Can-Fite BioPharma
Cantharidin Pharmaceuticals
Celgene
Cellceutix Corporation
CellPoint 
Celltrion 
Cerbios-Pharma
Checkmate Pharmaceuticals (Acquired by Regeneron)
Checkpoint Therapeutics
Chiesi Farmaceutici
Chugai Pharmaceutical
Cipher Pharmaceuticals
Clinuvel Pharmaceuticals
Coherus BioSciences
Concert Pharmaceuticals
Cosmo Pharmaceuticals
CSL Behring
Cubist Pharmaceuticals 
Cugene
Cumberland Pharmaceuticals
Daewoong Pharmaceutical
Daiichi Sankyo
Debiopharm
Depomed Inc
Dermata Therapeutics
Dermavant Sciences 
DermBiont
DFB Soria
DICE Therapeutics (Acquired by Lilly)
Dow
Dr. Reddy's Laboratories
Duke University
Durata Therapeutics
Dusa Pharmaceuticals
Eirion Therapeutics
Eli Lilly and Company
Elorac
Elsie Biotechnologies
EMD Serono
EPI Health
Equillium (Bioniz) 
Escalier Biosciences
Escient Pharmaceuticals (Acquired by Incyte Corporation)
European Medicines Agency (EMA) 
Evolus 
Ewopharma 
Exelixis 
Eywa Pharma Inc
F. Hoffmann-La Roche
FAES Farma 
U.S. Food and Drug Administration (FDA)
Fibrocell Science (Castle Creek Biosciences Inc.)
fosmanogepix
Fusion Pharmaceuticals
G&E Herbal Biotechnology 
Galapagos 
Galderma
Galectin Therapeutics
GammaDelta Therapeutics Limited
Genentech (Part of Roche)
Gilead Sciences
GlaxoSmithKline 
Glenmark Pharmaceuticals 
Gracell Biotechnologies
GSK (GlaxoSmithKline)
Gurnet Point Capital 
Hallux
Hapten Sciences 
Health Canada 
Horizon Therapeutics (Amgen)
Hoth Therapeutics 
Huya Bioscience
Ichnos Glenmark Innovation
Ichnos Sciences 
Immunocore
Immutep
Incyte Corporation 
Innovation Pharmaceuticals
InSite Vision
Iovance Biotherapeutics
Ipsen
Janssen Biotech
Janssen Pharmaceutical Companies 
Janssen Research & Development
Japan Tobacco
Jiangsu Hengrui Medicine
Johnson & Johnson 
Journey Medical Corporation
Kiniksa Pharmaceuticals
Kintara Therapeutics
Krystal Biotech
Kymera Therapeutics
Kyowa Kirin 
Ladrôme
Landos Biopharma
LEO Pharma 
Ligand Pharmaceuticals
Lipidor
Maruho
Mayne Pharma 
Meda Pharma
Medytox
Melinta Therapeutics
Merck & Co
Merck KGaA
Merz Pharma
Microsoft 
Moberg Pharma
Moderna 
MorphoSys
Mycovia Pharmaceuticals
Mylan 
Nabriva Therapeutics
Nanology
Neogene Therapeutics Inc.
Nestlé Skin Health
Neumedicines
Nielsen BioSciences 
Novartis
Novella Clinical
Novo Holdings
Oncolys Biopharma
Oncotelic
Ono Pharmaceutical Company 
Opsidio
OriCiro Genomics
Ortho Dermatologics (Bausch Health Companies)
Paratek Pharmaceuticals
Pelthos Therapeutics (Ligand Pharmaceuticals)
Pfizer
Pharmalucence
Philogen
Phio Pharmaceuticals
Photogen Technologies Inc.
Pierre Fabre Group
Pola Pharma 
Poli Group
Polichem (Almirall)
PolyMedix 
Polynoma
Precigen Inc
Prevail Therapeutics
Priovant Therapeutics
Promius Pharma 
ProQR Therapeutics
Proteologix 
Protomer Technologies
Provectus Biopharmaceuticals
Pyxis Oncology
Qurient
Ralexar Therapeutics
Rani Therapeutics
Regeneron Pharmaceuticals 
Roche Group 
Roche Holding (F. Hoffmann-La Roche)
Roivant Sciences
Salix Pharmaceuticals 
Samsung Bioepis 
Samsung Biologics 
Samsung Group
Sandoz 
Sanofi
Sato Pharmaceutical
SBI Biotech
Searchlight Pharma
Seattle Genetics
Sierra Oncology
Sinclair Pharma
Sol-Gel Technologies
Soligenix
Spectrum Pharmaceuticals
Spexis AG
Stiefel Laboratories 
Sun Pharmaceutical Industries
Takeda Oncology 
Takeda Pharmaceutical Company
Taro Pharmaceutical Industries 
Teva Pharmaceutical Industries 
The Medicines Company 
The Proactiv Company
ThermiGen
Timber Pharmaceuticals (Acquired by Leo Pharma)
Tioga Pharmaceuticals
Torii Pharmaceutical
Trillium Therapeutics
UCB
UNION Therapeutics
University of Pennsylvania 
Upjohn Business 
URL Pharma
Valeant
Vanda Pharmaceuticals
Vectans Pharma
Ventana Medical Systems
Verrica Pharamceuticals
Viatris
VidacPharma
Villaris Therapeutics (Acquired by Incyte Corporation) 
Vyne
Zai Lab 
Zydus Group (Cadila Healthcare)